Literature DB >> 19415691

Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C.

Nicole M Yanjanin1, Jorge I Vélez, Andrea Gropman, Kelly King, Simona E Bianconi, Sandra K Conley, Carmen C Brewer, Beth Solomon, William J Pavan, Mauricio Arcos-Burgos, Marc C Patterson, Forbes D Porter.   

Abstract

Niemann-Pick disease, type C is a neurodegenerative, lysosomal storage disorder with a broad clinical spectrum and a variable age of onset. The absence of a universally accepted clinical outcome measure is an impediment to the design of a therapeutic trial for NPC. Thus, we developed a clinical severity scale to characterize and quantify disease progression. Clinical signs and symptoms in nine major (ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, and swallowing) and eight minor (auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, and respiratory problems) domains were scored. Data were collected from 18 current NPC patients and were extracted from records of 19 patients. Both patient cohorts showed a linear increase in severity scores over time. Cross-sectional evaluation of current patients showed a linear increase in the severity score. Longitudinal chart review of historical data demonstrated that although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients. Combining the data from both cohorts, disease progression could be modeled by the following equation: ŝ(t0+x) = ŝ(t0) + 1.87x; where ŝ(t0) is the initial score and ŝ(t0+x) is the predicted future score after x years. Our observation that disease progression is similar across patients and independent of age of onset is consistent with a biphasic pathological model for NPC. This scale may prove useful in the characterization of potential biomarkers, and as an outcome measure to monitor disease progression in NPC patients. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 19415691      PMCID: PMC2798912          DOI: 10.1002/ajmg.b.30969

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  24 in total

Review 1.  The niemann-pick disease genes; regulators of cellular cholesterol homeostasis.

Authors:  Daniel S Ory
Journal:  Trends Cardiovasc Med       Date:  2004-02       Impact factor: 6.677

Review 2.  Therapy of Niemann-Pick disease, type C.

Authors:  Marc C Patterson; Frances Platt
Journal:  Biochim Biophys Acta       Date:  2004-10-11

3.  Progression of neurovisceral storage disease with supranuclear ophthalmoplegia following orthotopic liver transplantation.

Authors:  J C Gartner; I Bergman; J J Malatack; B J Zitelli; R Jaffe; J B Watkins; B W Shaw; S Iwatsuki; T E Starzl
Journal:  Pediatrics       Date:  1986-01       Impact factor: 7.124

4.  Critical role for glycosphingolipids in Niemann-Pick disease type C.

Authors:  M Zervas; K L Somers; M A Thrall; S U Walkley
Journal:  Curr Biol       Date:  2001-08-21       Impact factor: 10.834

5.  Identification of HE1 as the second gene of Niemann-Pick C disease.

Authors:  S Naureckiene; D E Sleat; H Lackland; A Fensom; M T Vanier; R Wattiaux; M Jadot; P Lobel
Journal:  Science       Date:  2000-12-22       Impact factor: 47.728

Review 6.  Niemann-Pick disease type C.

Authors:  M T Vanier; G Millat
Journal:  Clin Genet       Date:  2003-10       Impact factor: 4.438

7.  Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon 4 homozygosity.

Authors:  Yuko Saito; Kinuko Suzuki; Eiji Nanba; Toshiyuki Yamamoto; Kousaku Ohno; Shigeo Murayama
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

8.  Niemann-pick disease type C in neonatal cholestasis at a North American Center.

Authors:  Baruch Yerushalmi; Ronald J Sokol; Michael R Narkewicz; Debra Smith; Josephine W Ashmead; David A Wenger
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-07       Impact factor: 2.839

9.  Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone.

Authors:  Lisa D Griffin; Wenhui Gong; Lucie Verot; Synthia H Mellon
Journal:  Nat Med       Date:  2004-06-20       Impact factor: 53.440

10.  NPC-db, a Niemann-Pick type C disease gene variation database.

Authors:  Heiko Runz; Dirk Dolle; Anna Melissa Schlitter; Johannes Zschocke
Journal:  Hum Mutat       Date:  2008-03       Impact factor: 4.878

View more
  97 in total

1.  Niemann-Pick disease type C: analysis of 7 patients.

Authors:  Hui Xiong; Xin-Hua Bao; Yue-Hua Zhang; You-Ning Xu; Jiong Qin; Hui-Ping Shi; Xi-Ru Wu
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma.

Authors:  Xuntian Jiang; Rohini Sidhu; Forbes D Porter; Nicole M Yanjanin; Anneliese O Speak; Danielle Taylor te Vruchte; Frances M Platt; Hideji Fujiwara; David E Scherrer; Jessie Zhang; Dennis J Dietzen; Jean E Schaffer; Daniel S Ory
Journal:  J Lipid Res       Date:  2011-04-24       Impact factor: 5.922

Review 3.  Niemann-pick disease type C: implications for sedation and anesthesia for diagnostic procedures.

Authors:  Ning Miao; Xiaowei Lu; Naomi P O'Grady; Nicole Yanjanin; Forbes D Porter; Zenaide M N Quezado
Journal:  J Child Neurol       Date:  2012-02-28       Impact factor: 1.987

4.  Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.

Authors:  A Cougnoux; S Clifford; A Salman; S-L Ng; J Bertin; F D Porter
Journal:  Mol Genet Metab       Date:  2018-10-30       Impact factor: 4.797

5.  FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.

Authors:  Jason Newton; Nitai C Hait; Michael Maceyka; Alexandria Colaco; Melissa Maczis; Christopher A Wassif; Antony Cougnoux; Forbes D Porter; Sheldon Milstien; Nicholas Platt; Frances M Platt; Sarah Spiegel
Journal:  FASEB J       Date:  2017-01-12       Impact factor: 5.191

6.  Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease.

Authors:  Forbes D Porter; David E Scherrer; Michael H Lanier; S Joshua Langmade; Vasumathi Molugu; Sarah E Gale; Dana Olzeski; Rohini Sidhu; Dennis J Dietzen; Rao Fu; Christopher A Wassif; Nicole M Yanjanin; Steven P Marso; John House; Charles Vite; Jean E Schaffer; Daniel S Ory
Journal:  Sci Transl Med       Date:  2010-11-03       Impact factor: 17.956

Review 7.  Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases.

Authors:  Juan Eduardo Megías-Vericat; Ana García-Robles; María José Company-Albir; María José Fernández-Megía; Francisco Carlos Pérez-Miralles; Eduardo López-Briz; Bonaventura Casanova; José Luis Poveda
Journal:  Neurol Sci       Date:  2017-02-02       Impact factor: 3.307

8.  Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).

Authors:  J M Kwon; H Adams; P G Rothberg; E F Augustine; F J Marshall; E A Deblieck; A Vierhile; C A Beck; N J Newhouse; J Cialone; E Levy; D Ramirez-Montealegre; L S Dure; K R Rose; J W Mink
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

Review 9.  Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Authors:  Elizabeth A Ottinger; Mark L Kao; Nuria Carrillo-Carrasco; Nicole Yanjanin; Roopa Kanakatti Shankar; Marjo Janssen; Marcus Brewster; Ilona Scott; Xin Xu; Jim Cradock; Pramod Terse; Seameen J Dehdashti; Juan Marugan; Wei Zheng; Lili Portilla; Alan Hubbs; William J Pavan; John Heiss; Charles H Vite; Steven U Walkley; Daniel S Ory; Steven A Silber; Forbes D Porter; Christopher P Austin; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 10.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.